Diffuse Large B-Cell Lymphoma

Featured Article
Optimal Treatment Dosing for Patients With DLBCL
According to study findings published online in Cancer Chemotherapy and Pharmacology, researchers identified the optimal dose of selinexor in patients with diffuse large B-cell.
Neurologic Adverse Events from DLBCL Treatment Boost Health Care Costs
According to study findings, neurologic toxicities from treatment for relapsed or refractory diffuse large B-cell lymphoma increased total health care costs more than $70,000 on average for US…
DLBCL Costs Per US Patient Substantial, Real-World Study Shows
Per-patient-per-year costs for DLBCL in the United States are considerable, with many patients requiring treatment beyond their first line of therapy, according to a real-world study.

Newsfeed

Optimal Treatment Dosing for Patients With DLBCL
Neurologic Adverse Events from DLBCL Treatment Boost Health Care Costs
DLBCL Costs Per US Patient Substantial, Real-World Study Shows
Identifying New Standard of Care for Patients With DLBCL
Encouraging Survival Rates With Treatment Regimen for High-Risk DLBCL
Reviewing a Cost-Effective Treatment Option for RR DLBCL
Real-World Findings Question CAR-T Therapy’s Benefit Over Other Therapies for DLBCL
Potential New Standard of Care Identified for Patients With DLBCL
View More

Interactive Features

Identifying New Standard of Care for Patients With DLBCL
True or False: Skipping radiation and receiving less chemotherapy may become the new standard of care.
View More
Back to Top